Martek Biosciences Corporation Announces Settlement of Patent Dispute with Capsugel France

Published: Sep 10, 2009

COLUMBIA, Md., Sept. 10 /PRNewswire-FirstCall/ -- DHA omega-3 innovator and maker of the life'sDHA(TM) brand, Martek Biosciences Corporation , announced today it has resolved a patent dispute with Capsugel France. The resolution follows Martek's November 2008 action for infringement filed in the High Court of Strasbourg, France.

This settlement agreement between Martek and Capsugel does not include Martek's action against Lonza Ltd AG, which continues.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2008 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

Martek Biosciences Corporation



Back to news